# US 2009/0025096 A1 · P4has as modifiers of the igfr pathway and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0025096 A1
- Document ID: US20090025096A1
- Status: Published application
- Kind: A1
- Application number: 11/628,561
- Filed: 2005-06-20
- Published: 2009-01-22
- Earliest claimed: 2004-06-21
- Assignees: Exelixis, Inc.
- Inventors: Lori S. Friedman; Helen Francis-Lang; Annette L. Parks; Kenneth James Shaw; Timothy S. Heuer; Lynn Margaret Bjerke
- Web page: https://patentgrep.com/patent/US20090025096A1

## CPC

- C12Q 1/485: {involving kinase}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12Q 1/26: involving oxidoreductase
- C12Q 1/68: involving nucleic acids
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Y 114/11002: Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase
- G01N 33/575: for cancer
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided.

## Claims

### Claim 1

A method of identifying a candidate IGFR pathway modulating agent, said method comprising the steps of:
(a) providing an assay system comprising a P4HA polypeptide or nucleic acid;
(b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
(c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate IGFR pathway modulating agent.

### Claim 2 (depends on 1)

The method of claim 1 wherein the assay system comprises cultured cells that express the P4HA polypeptide.

### Claim 3 (depends on 2)

The method of claim 2 wherein the cultured cells additionally have defective IGFR function.

### Claim 4 (depends on 1)

The method of claim 1 wherein the assay system includes a screening assay comprising a P4HA polypeptide, and the candidate test agent is a small molecule modulator.

### Claim 5 (depends on 4)

The method of claim 4 wherein the assay is a hydroxylase assay.

### Claim 6 (depends on 1)

The method of claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.

### Claim 7 (depends on 1)

The method of claim 1 wherein the assay system includes a binding assay comprising a P4HA polypeptide and the candidate test agent is an antibody.

### Claim 8 (depends on 1)

The method of claim 1 wherein the assay system includes an expression assay comprising a P4HA nucleic acid and the candidate test agent is a nucleic acid modulator.

### Claim 9 (depends on 8)

The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

### Claim 10 (depends on 8)

The method of claim 8 wherein the nucleic acid modulator is a PMO.

### Claim 11 (depends on 1)

The method of claim 1 additionally comprising:
(d) administering the candidate IGFR pathway modulating agent identified in (c) to a model system comprising cells defective in IGFR function and, detecting a phenotypic change in the model system that indicates that the IGFR function is restored.

### Claim 12 (depends on 11)

The method of claim 11 wherein the model system is a mouse model with defective IGFR function.

### Claim 13

A method for modulating a IGFR pathway of a cell comprising contacting a cell defective in IGFR function with a candidate modulator that specifically binds to a P4HA polypeptide, whereby IGFR function is restored.

### Claim 14 (depends on 13)

The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in IGFR function.

### Claim 15 (depends on 13)

The method of claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

### Claim 16 (depends on 1)

The method of claim 1, comprising the additional steps of:
(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing P4HA,
(e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and
(f) detecting an agent-biased activity of the second assay system,
wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate IGFR pathway modulating agent,
and wherein the second assay detects an agent-biased change in the IGFR pathway.

### Claim 17 (depends on 16)

The method of claim 16 wherein the secondary assay system comprises cultured cells.

### Claim 18 (depends on 16)

The method of claim 16 wherein the secondary assay system comprises a non-human animal.

### Claim 19 (depends on 18)

The method of claim 18 wherein the non-human animal mis-expresses an IGFR pathway gene.

### Claim 20

A method of modulating IGFR pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a P4HA polypeptide or nucleic acid.

### Claim 21 (depends on 20)

The method of claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

### Claim 22 (depends on 20)

The method of claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

### Claim 23

A method for diagnosing a disease in a patient comprising:
obtaining a biological sample from the patient;
contacting the sample with a probe for P4HA expression;
comparing results from step (b) with a control;
determining whether step (c) indicates a likelihood of disease.

### Claim 24 (depends on 23)

The method of claim 23 wherein said disease is cancer.

### Claim 25 (depends on 24)

The method according to claim 24, wherein said cancer is a cancer as shown in Table 1 as having >25% expression level.
